Cumberland Pharmaceuticals (CPIX) Amortization of Deferred Charges (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) reported Amortization of Deferred Charges of $285184.0 for Q1 2026, up 5218.61% on a YoY basis from $5362.0 in Q1 2025, and up 134.26% sequentially from -$832368.0 in Q4 2025.
Cumberland Pharmaceuticals (CPIX) Amortization of Deferred Charges (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals (CPIX) has 17 years of Amortization of Deferred Charges data on file, last reported at $285184.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges rose 5218.61% year-over-year to $285184.0; the trailing twelve-month figure through Mar 2026 stood at $303007.0 (down 73.47% YoY), and the FY2025 full-year result was $23185.0, down 97.97% from the prior year.
- Amortization of Deferred Charges grew to $285184.0 in Q1 2026, from -$832368.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $846899.0 in Q3 2024 to a low of -$832368.0 in Q4 2025.
- A 5-year average of $134990.8 and a median of $4844.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Peak annual rise in Amortization of Deferred Charges reached 22572.55% in 2023, while the deepest fall reached 6403.68% in 2023.
- Tracing CPIX's Amortization of Deferred Charges over 5 years: stood at $3629.0 in 2022, then soared by 22572.55% to $822787.0 in 2023, then sank by 65.34% to $285185.0 in 2024, then tumbled by 391.87% to -$832368.0 in 2025, then jumped by 134.26% to $285184.0 in 2026.
- Business Quant data shows CPIX's Amortization of Deferred Charges at $285184.0 in Q1 2026, -$832368.0 in Q4 2025, and $285184.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Cumberland Pharmaceuticals | 104.57 Mn | 93.23 Mn | 7.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 285,184.00 |
| Mar 31, 2026 | 285,184.00 |
| Dec 31, 2025 | -832,368.00 |
| Dec 31, 2025 | -832,368.00 |
| Sep 30, 2025 | 285,184.00 |
| Sep 30, 2025 | 285,184.00 |
| Jun 30, 2025 | 565,007.00 |
| Jun 30, 2025 | 565,007.00 |
| Mar 31, 2025 | 5,362.00 |
| Mar 31, 2025 | 5,362.00 |
| Dec 31, 2024 | 285,185.00 |
| Dec 31, 2024 | 285,185.00 |
| Sep 30, 2024 | 846,899.00 |
| Sep 30, 2024 | 846,899.00 |
| Jun 30, 2024 | 4,844.00 |
| Jun 30, 2024 | 4,844.00 |
| Mar 31, 2024 | 3,810.00 |
| Mar 31, 2024 | 3,810.00 |
| Dec 31, 2023 | 822,787.00 |
| Dec 31, 2023 | 822,787.00 |